The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Authors
Stephanie Lustgarten
Charlie Gourley (ORCID: https://orcid.org/0000-0002-2377-7221)
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Stephanie Lustgarten, Charlie Gourley, Alessandro Davide Santin, Bradley J. Monk et al.
Citations
1 citations
Journal
Future Oncology
Topics
Ovarian cancer diagnosis and treatment
Field-Weighted Citation Impact (FWCI)
1.70
article
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Stephanie Lustgarten, Charlie Gourley, Alessandro Davide Santin, Bradley J. Monk, David M. O’Malley, Premal H. Thaker, Véronique D’Hondt, Rachel N. Grisham, Andrew R. Clamp, Robert W. Holloway, Manuel Rodrigues, Carol Aghajanian, Kari Lassen Ring, Susana Banerjee, Hagop Youssoufian, Ana Oaknin, Kathleen N. Moore, Emily Prendergast, Toon Van Gorp, Gregg Newman, Nicoletta Colombo, Christine Gennigens, Hye Sook Chon, E. Salinas, Els Van Nieuwenhuysen
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Future OncologyVol. 21(30)
Institutions
Royal Marsden NHS Foundation Trust (GB), Memorial Sloan Kettering Cancer Center (US), Inserm (FR), University of Liège (BE), Washington University in St. Louis (US), Cornell University (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Sansum Medical Clinic (US), Edinburgh Cancer Research (GB), Moffitt Cancer Center (US), Yale University (US), Florida Hospital Cancer Institute (US), VIB-KU Leuven Center for Cancer Biology (BE), Florida Cancer Specialists & Research Institute (US), Vall d'Hebron Hospital Universitari (ES), The Christie NHS Foundation Trust (GB), Centre Hospitalier Universitaire de Liège (BE), Institut de Recherche en Cancérologie de Montpellier (FR), Nebraska Cancer Specialists (US), Verastem (United States) (US), Minnesota Oncology (US), Vall d'Hebron Institute of Oncology (ES), University of Oklahoma Health Sciences Center (US), University of Virginia (US), The Ohio State University (US), European Institute of Oncology (IT), University of Milano-Bicocca (IT), Institut Curie (FR), KU Leuven (BE)